Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of intraperitoneal Radspherin in HR-proficient advanced ovarian-related cancers with peritoneal metastasis
2023-508497-28-00Phase 2Authorised
- Sponsor
- Oncoinvent ASA
- Start
- Jun 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of Radspherin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by Oncoinvent ASA. Primary endpoint: Progression-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
Radspherin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2023-508497-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508497-28-00.